Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3112-3122

  Jensen, Ana R ^a   Saito, Y David ^a   Liao, Chuanhong ^a   Dai, Jinlu ^c   Keller, Evan T ^c   Al Ahmadie, Hikmat ^d   Dakin Haché, Kelly ^b   Usatyuk, Peter ^b   Sievert, Margarit F ^a   Paner, Gladell P ^a   Yala, Soheil ^a   Cervantes, Gustavo M ^a   Natarajan, Viswanathan ^b   Salgia, Ravi ^a   Posadas, Edwin M ^a,e  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE FYN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL MOTILITY; CELL SHAPE; CELL STRAIN; CELL STRAIN PC3; CHEMOTAXIS; CONTROLLED STUDY; DOWNSTREAM PROCESSING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TIME LAPSE IMAGING; TISSUE MICROARRAY; TROPISM; VIDEORECORDING;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SHAPE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FYN; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TROPISM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956017934     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1264     Document Type: Article

References (25)

1. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, et al. FYN is overexpressed in human prostate cancer. BJU Int 2009;103:171-7.
2. Alland L, Peseckis SM, Atherton RE, Berthiaume L, Resh MD. Dual myristylation and palmitylation of Src family member p59fyn affects subcellular localization. J Biol Chem 1994;269:16701-5.
3. Liang X, Lu Y, Wilkes M, Neubert TA, Resh MD. The N-terminal SH4 region of the Src family kinase Fyn is modified by methylation and heterogeneous fatty acylation: role in membrane targeting, cell adhesion, and spreading. J Biol Chem 2004;279:8133-9. (Pubitemid 38294704)
4. Calautti E, Grossi M, Mammucari C, Aoyama Y, Pirro M, Ono Y, et al. Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in keratinocyte cell-cell adhesion. J Cell Biol 2002;156:137-48. (Pubitemid 34846942)
5. Cary LA, Chang JF, Guan JL. Stimulation of cell migration by over-expression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci 1996;109(Pt 7):1787-94. (Pubitemid 26248624)
6. Reddy KB, Smith DM, Plow EF. Analysis of Fyn function in hemostasis and alphaIIbbeta3-integrin signaling. J Cell Sci 2008;121:1641-8. (Pubitemid 351911821)
7. Wolf RM, Wilkes JJ, Chao MV, Resh MD. Tyrosine phosphorylation of p190 RhoGAP by Fyn regulates oligodendrocyte differentiation. J Neurobiol 2001;49:62-78.
8. Zamoyska R, Basson A, Filby A, Legname G, Lovatt M, Seddon B. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol Rev 2003;191:107-18. (Pubitemid 36398852)
9. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96.
10. Davies G, Jiang WG, Mason MD. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. In: Albin RJ, Mason MD, editors. Metastasis of Prostate Cancer. Netherlands: Springer; 2008:197-219.
11. Zicha D, Dunn G, Jones G. Analyzing chemotaxis using the Dunn direct-viewing chamber. Methods Mol Biol 1997;75:449-57.
12. Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, et al. Upregulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol 2007;212:386-94. (Pubitemid 47099015)
13. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001;48:47-53.
14. Zar Jerrold H. Biostatistical Analysis. 5th Edition, 2010. Pearson Prentice-Hall, Upper Saddle River, NJ.
15. Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 1994;24:46-53. (Pubitemid 24050586)
16. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005;92:320-7. (Pubitemid 40343148)
17. Resh MD. Fyn, a Src family tyrosine kinase. Int J Biochem Cell Biol 1998;30:1159-62. (Pubitemid 28515659)
18. Stein PL, Lee HM, Rich S, Soriano P. pp59fyn mutant mice display differential signalingin thymocytes andperipheral T cells.Cell 1992;70:741-50.
19. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33.
20. Liu X, Du J, Wang G, Chen Z, Wang W, XiQ, et al. Roles of Fyn in pancreatic cancer metastasis. J Gastroenterol Hepatol 2010;25:293-301.
21. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421-8.
22. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Biol Ther 2009;8:2153-9.
23. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 2009;8:2153-9.
24. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 2010;29:3196-207.
25. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium Study. Anticancer Drugs 2009;20:179-84.